• Overview

    Lyvgen's CD137(4-1BB) bispecific antibodies and CD40 bispecific antibodies are available for licensing-out or collaboration. Contact: luyan.liu@lyvgen.com

    Lyvgen Biopharma engaged in development of innovative cancer treatment, aims to in-license advanced clinical candidate drugs in order to enrich our pipeline. Please contact us to explore collaboration opportunities.